Drug Trial Radar · NCT04853329
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
7
Actual
Start
Dec 13, 2021
Primary completion
Jan 31, 2023
Study completion Jan 31, 2023
Sponsor
- Lead sponsor
- Conjupro Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available.
Conditions
- CD20 Positive Non Hodgkin Lymphoma
Interventions
CPO107Drug
CD20-CD47 Bispecific Fusion Protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the recommended single-agent CPO107 RP2DTime frame: through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novant Health
Charlotte, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.